Lọc theo danh mục
  • Năm xuất bản
    Xem thêm
  • Lĩnh vực
liên kết website
Lượt truy cập
 Lượt truy cập :  25,092,315
  • Công bố khoa học và công nghệ Việt Nam

76.29.37

Y học lâm sàng

Cấn Thị Bích Ngọc(2), Vũ Chí Dũng(1), Nguyễn Ngọc Khánh, Nguyễn Thị Hoài, Bùi Phương Thảo, Khu Thị Khánh Dung, Nguyễn Thanh Liêm, Seiji Yamaguchi

Kiểu hình và kết quả điều trị bệnh rối loạn chuyển hóa Axit hữu cơ propionic máu

Phenotype and outcome of propionic acidemia treatment

Y học Việt Nam

2012

DB

194-198

1859-1868

Propionic acidemia (PPA) is an autosomal recessive metabolic disease resulting from a deficiency of propionyl CoA. carboxylase activity. Objective: To describle clinical features and laboratory finding of patients with PPA and to evaluate outcome of management. Subjects and methods: This is a case series report. Clinical features, biochemical finding and management outcome of 8 Vietnamese cases from 8 unrelated families were study. GS/MS and Tandem mass were performed in Shimane University - Japan. Rerults: 4/8 families had more than 2 affected children. 6/8 cases had acute metabolic decompensation with onset age 1 year, among them 4/8 cases had clinical symptoms in neonatal period. Clinical manifestations of the acute episodes were lethagy/coma (7/8), convulsion (6/8), hypotonia (6/8), dehydration due to vommiting (5/8). In acute episodes, laboratory findings showed metabolic acidosis (7/8), hyperamonemia (7/8), thrompenia (6/8) and neutropenia (5/8) ketouria (4/6). There were poor prognosis in patients with PPA: 5/8 cases died during acute episodes, median age of death were 9.9 months (min 16 days - max 28 months). Among them, 4 cases died in the neonatal period. 3 case has motor and mental retardation. Conclusions: Propionic acidemia is an organic acidemia known to bring about a syndrome of ketoacidosis, lethargy/coma, convulsion, hypotonia and vomiting, to present in the newborn period. This disorder results in neurological impairment or death, if not properly controlled. It is important to perform screening for high risk infants, newborn screening and early diagnosis to reduce mortality and neurologic consequence of patients with PPA.

TTKHCNQG, CVv46